Arrowhead Research Corporation Subsidiary Unidym, Inc. Licenses Technology to Incorporate Carbon Nanotubes into Miniaturized Medical Devices for the Treatment of Cardiovascular Disease

Published: Aug 03, 2007

PASADENA, Calif. & CHARLESTON, W.Va.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ:ARWR) and Paragon Intellectual Properties, LCC announced today that Arrowhead’s majority-owned subsidiary, Unidym Inc., has signed an exclusive license agreement with Paragon’s majority-owned subsidiary, Nanotech Catheter Solutions, LLC (NCS). NCS will use Unidym’s carbon nanotube technology in the development of medical devices for the treatment of cardiovascular disease. Under the terms of the agreement, Unidym will receive a 20 percent equity stake in NCS, and the parties will negotiate a supply agreement or royalty.

Back to news